US
CA
NZ
UK
AU
IND
Last update at 2025-05-16T16:57:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
ARWR: Multiple Value Drivers for Long-Term Growth…
Thu 15 May 25, 10:10 AMArrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...
Tue 13 May 25, 07:07 AMArrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
Mon 12 May 25, 08:01 PMSRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
Wed 07 May 25, 12:31 PMArrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now
Thu 20 Feb 25, 05:15 PMARWR: Multiple Catalysts Ahead in 2025…
Wed 12 Feb 25, 02:22 PM| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | -206.49100M | -172.70900M | -140.84600M | -84.55083M | 68.15M |
| Minority interest | 4.00M | -0.43100M | - | - | -0.55519M |
| Net income | -205.27500M | -176.49400M | -140.84800M | -84.55323M | 67.97M |
| Selling general administrative | 92.55M | 124.43M | 80.98M | 52.28M | 26.56M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 240.74M | 243.23M | 138.29M | 87.99M | 168.80M |
| Reconciled depreciation | 12.49M | 10.42M | 8.27M | 5.94M | 4.44M |
| Ebit | -200.65800M | -188.92800M | -149.03600M | -93.15880M | 61.19M |
| Ebitda | -188.16500M | -178.50700M | -140.76900M | -87.21654M | 65.63M |
| Depreciation and amortization | 12.49M | 10.42M | 8.27M | 5.94M | 4.44M |
| Non operating income net other | - | 0.77M | 2.07M | -0.58252M | - |
| Operating income | -205.00200M | -178.50700M | -149.03600M | -93.15880M | 61.19M |
| Other operating expenses | 445.74M | 421.74M | 287.32M | 181.15M | 107.60M |
| Interest expense | 18.33M | 5.03M | 6.12M | 9190.50M | 6957.77M |
| Tax provision | 2.78M | 3.79M | 0.00200M | 0.00240M | 0.17M |
| Interest income | 15.30M | - | - | - | 6.96M |
| Net interest income | -3.02700M | 5.03M | 6.12M | 9.19M | 6.96M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 2.78M | 3.79M | 0.00200M | 0.00240M | 0.17M |
| Total revenue | 240.74M | 243.23M | 138.29M | 87.99M | 168.80M |
| Total operating expenses | 445.74M | 421.74M | 287.32M | 181.15M | 107.60M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 1.54M | 5.80M | 8.19M | 8.61M | 6.96M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -209.27500M | -172.70900M | -140.84800M | -84.55323M | 67.97M |
| Net income applicable to common shares | - | -176.06300M | -140.84800M | -84.55323M | 67.97M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Total assets | 1139.80M | 765.55M | 691.94M | 710.15M | 522.50M |
| Intangible assets | 8.56M | 10.26M | 11.96M | 13.66M | 15.36M |
| Earning assets | - | - | - | - | - |
| Other current assets | 14.51M | 7.08M | 20.20M | 2.19M | 1.78M |
| Total liab | 948.74M | 478.39M | 585.98M | 301.33M | 60.72M |
| Total stockholder equity | 185.44M | 271.34M | 105.96M | 408.82M | 461.78M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 85.44M | -46.42900M | -5.64400M | 23.77M | 13.47M |
| Common stock | 0.22M | 0.20M | 105.96M | 0.20M | 0.19M |
| Capital stock | 0.22M | 0.20M | 105.96M | 0.20M | 0.19M |
| Retained earnings | -1625.52300M | -1026.03000M | -820.75500M | -644.69200M | -503.84419M |
| Other liab | - | - | 55.95M | 190.27M | 41.43M |
| Good will | - | - | - | - | 15.36M |
| Other assets | - | - | 0.22M | 96.76M | 68.87M |
| Cash | 102.69M | 110.89M | 108.00M | 184.43M | 143.58M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 103.17M | 0.87M | 74.10M | 146.54M | 40.68M |
| Current deferred revenue | - | 0.87M | 74.10M | 111.06M | 19.29M |
| Net debt | 14.68M | 4.28M | -26.42900M | -158.88900M | -122.44471M |
| Short term debt | 6.34M | 10.56M | 2.78M | 2.25M | 1.09M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 117.37M | 115.17M | 81.58M | 25.55M | 21.14M |
| Other stockholder equity | 1806.00M | 1300.39M | 820.89M | 1053.39M | 965.41M |
| Property plant equipment | - | - | 110.30M | 48.67M | 30.88M |
| Total current assets | 695.47M | 110.89M | 376.40M | 384.60M | 322.37M |
| Long term investments | - | 292.74M | 105.87M | 245.59M | 137.49M |
| Net tangible assets | - | - | 398.52M | 395.16M | 446.42M |
| Short term investments | 578.28M | 292.74M | 268.39M | 183.35M | 171.91M |
| Net receivables | - | 0.00000M | 1.41M | 10.26M | 0.85M |
| Long term debt | 393.18M | - | - | - | - |
| Inventory | - | - | -21.61400M | 4.36M | 4.25M |
| Accounts payable | 11.39M | 35.87M | 2.87M | 9.46M | 6.83M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | 19.82M | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 4.75M | -3.22200M | -0.13600M | -0.06900M | 0.02M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.20M | 0.20M | 0.19M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -820.75500M | -644.69200M | -503.84419M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 4.48M | 361.93M | 29.12M | 0.27M | 0.27M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 444.33M | 654.66M | 315.54M | 325.55M | 200.13M |
| Capital lease obligations | 117.37M | 115.17M | 81.58M | 25.55M | 21.14M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -96.15500M | 47.36M | -118.11100M | -228.82605M | -47.74601M |
| Change to liabilities | - | 11.23M | 13.38M | 3.40M | 87.65M |
| Total cashflows from investing activities | - | -5.41700M | -141.67800M | -240.77776M | -47.74601M |
| Net borrowings | - | - | - | - | -2.41515M |
| Total cash from financing activities | 253.05M | 65.19M | 11.30M | 257.95M | 66.38M |
| Change to operating activities | - | 11.95M | 10.39M | 3.83M | -0.15547M |
| Net income | -209.27500M | -176.49400M | -140.84800M | -84.55323M | 67.97M |
| Change in cash | 2.89M | -76.42900M | 40.85M | -78.22146M | 191.67M |
| Begin period cash flow | 108.00M | 184.43M | 143.58M | 221.80M | 30.13M |
| End period cash flow | 110.89M | 108.00M | 184.43M | 143.58M | 221.80M |
| Total cash from operating activities | -153.89000M | -136.13100M | 171.22M | -95.39157M | 173.03M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 250.48M | 60.52M |
| Depreciation | 12.49M | 10.42M | 8.27M | 5.94M | 4.44M |
| Other cashflows from investing activities | - | - | - | - | -35.74478M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -3.36200M | - | 9.16M | 1.60M | -1.26044M |
| Change to account receivables | 1.41M | 8.85M | -9.40900M | -0.18431M | -0.33399M |
| Sale purchase of stock | - | 5.19M | 11.30M | 257.95M | 68.80M |
| Other cashflows from financing activities | 253.05M | 60.00M | 11.30M | 7.47M | 8.28M |
| Change to netincome | - | 125.33M | 76.67M | 43.38M | 13.46M |
| Capital expenditures | 176.74M | 52.78M | 23.57M | 11.95M | 12.00M |
| Change receivables | - | 8.85M | -9.40900M | -0.18431M | - |
| Cash flows other operating | - | -118.36400M | 222.90M | -63.90116M | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -76.36200M | 40.85M | -78.22146M | - |
| Change in working capital | -51.54700M | -98.29300M | 226.87M | -60.68890M | 87.16M |
| Stock based compensation | 78.13M | 120.89M | 76.67M | 43.38M | 12.39M |
| Other non cash items | 50.72M | 7.34M | 0.27M | 0.53M | 1.07M |
| Free cash flow | -330.62700M | -188.90800M | 147.66M | -107.34328M | 161.03M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals Inc |
0.26 1.66% | 15.60 | - | 111.11 | 151.49 | 15.61 | 767.44 | -11.0198 |
| NVO Novo Nordisk A/S |
-2.13 3.22% | 64.02 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-2.15 3.28% | 63.40 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-0.34 0.08% | 434.04 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
3.10 0.53% | 588.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
177 East Colorado Boulevard, Pasadena, CA, United States, 91105
| Name | Title | Year Born |
|---|---|---|
| Dr. Christopher R. Anzalone Ph.D. | CEO, Pres & Director | 1969 |
| Mr. Kenneth A. Myszkowski | Chief Financial Officer | 1966 |
| Mr. Patrick O'Brien J.D., PharmD | COO & Gen. Counsel | 1964 |
| Dr. James C. Hamilton M.D., MBA | Sr. VP of Discovery & Translational Medicine | 1979 |
| Dr. Javier San Martin M.D. | Chief Medical Officer | 1965 |
| Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando | NA |
| Dr. Vincent Anzalone CFA | Head of Investor Relations & VP | NA |
| Mr. Howard Lovy | Director of Communications | NA |
| Dr. Mark Seefeld | Head of Toxicology & VP | 1954 |
| Ms. Tracie Oliver | Chief Commercial Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...